GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GNI Group Ltd (OTCPK:GNIIF) » Definitions » Cyclically Adjusted Price-to-FCF

GNI Group (GNI Group) Cyclically Adjusted Price-to-FCF : (As of Jun. 13, 2024)


View and export this data going back to 2013. Start your Free Trial

What is GNI Group Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


GNI Group Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for GNI Group's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GNI Group Cyclically Adjusted Price-to-FCF Chart

GNI Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1,218.61

GNI Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 1,218.61 3,384.08

Competitive Comparison of GNI Group's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, GNI Group's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GNI Group's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GNI Group's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GNI Group's Cyclically Adjusted Price-to-FCF falls into.



GNI Group Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

GNI Group's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, GNI Group's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.084/107.2000*107.2000
=-0.084

Current CPI (Mar. 2024) = 107.2000.

GNI Group Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.000 98.000 0.000
201409 0.000 98.500 0.000
201412 0.000 97.900 0.000
201503 -0.089 97.900 -0.097
201506 -0.042 98.400 -0.046
201509 -0.038 98.500 -0.041
201512 0.011 98.100 0.012
201603 -0.060 97.900 -0.066
201606 -0.063 98.100 -0.069
201609 -0.014 98.000 -0.015
201612 -0.005 98.400 -0.005
201703 -0.014 98.100 -0.015
201706 -0.056 98.500 -0.061
201709 -0.092 98.800 -0.100
201712 0.010 99.400 0.011
201803 0.031 99.200 0.034
201806 -0.077 99.200 -0.083
201809 -0.032 99.900 -0.034
201812 0.030 99.700 0.032
201903 -0.009 99.700 -0.010
201906 0.033 99.800 0.035
201909 0.014 100.100 0.015
201912 0.001 100.500 0.001
202003 0.097 100.300 0.104
202006 0.032 99.900 0.034
202009 0.090 99.900 0.097
202012 -0.006 99.300 -0.006
202103 0.278 99.900 0.298
202106 -0.098 99.500 -0.106
202109 -0.118 100.100 -0.126
202112 -0.078 100.100 -0.084
202203 0.022 101.100 0.023
202206 -0.045 101.800 -0.047
202209 -0.169 103.100 -0.176
202212 -0.034 104.100 -0.035
202303 0.038 104.400 0.039
202306 -0.059 105.200 -0.060
202309 0.396 106.200 0.400
202312 0.238 106.800 0.239
202403 -0.084 107.200 -0.084

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GNI Group  (OTCPK:GNIIF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


GNI Group Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of GNI Group's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GNI Group (GNI Group) Business Description

Industry
Traded in Other Exchanges
Address
Shinjuku Park Tower, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, JPN, 163-1030
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.

GNI Group (GNI Group) Headlines